The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNAi Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Small Molecule Interfering Ribonucleic Acid (SiRNA)
1.2.3 Microrna (MiRNA)
1.3 Market by Application
1.3.1 Global RNAi Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNAi Therapy Market Perspective (2018-2029)
2.2 RNAi Therapy Growth Trends by Region
2.2.1 Global RNAi Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 RNAi Therapy Historic Market Size by Region (2018-2023)
2.2.3 RNAi Therapy Forecasted Market Size by Region (2024-2029)
2.3 RNAi Therapy Market Dynamics
2.3.1 RNAi Therapy Industry Trends
2.3.2 RNAi Therapy Market Drivers
2.3.3 RNAi Therapy Market Challenges
2.3.4 RNAi Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNAi Therapy Players by Revenue
3.1.1 Global Top RNAi Therapy Players by Revenue (2018-2023)
3.1.2 Global RNAi Therapy Revenue Market Share by Players (2018-2023)
3.2 Global RNAi Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNAi Therapy Revenue
3.4 Global RNAi Therapy Market Concentration Ratio
3.4.1 Global RNAi Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNAi Therapy Revenue in 2022
3.5 RNAi Therapy Key Players Head office and Area Served
3.6 Key Players RNAi Therapy Product Solution and Service
3.7 Date of Enter into RNAi Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNAi Therapy Breakdown Data by Type
4.1 Global RNAi Therapy Historic Market Size by Type (2018-2023)
4.2 Global RNAi Therapy Forecasted Market Size by Type (2024-2029)
5 RNAi Therapy Breakdown Data by Application
5.1 Global RNAi Therapy Historic Market Size by Application (2018-2023)
5.2 Global RNAi Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America RNAi Therapy Market Size (2018-2029)
6.2 North America RNAi Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America RNAi Therapy Market Size by Country (2018-2023)
6.4 North America RNAi Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNAi Therapy Market Size (2018-2029)
7.2 Europe RNAi Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe RNAi Therapy Market Size by Country (2018-2023)
7.4 Europe RNAi Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNAi Therapy Market Size (2018-2029)
8.2 Asia-Pacific RNAi Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific RNAi Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific RNAi Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNAi Therapy Market Size (2018-2029)
9.2 Latin America RNAi Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America RNAi Therapy Market Size by Country (2018-2023)
9.4 Latin America RNAi Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNAi Therapy Market Size (2018-2029)
10.2 Middle East & Africa RNAi Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa RNAi Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa RNAi Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam
11.1.1 Alnylam Company Detail
11.1.2 Alnylam Business Overview
11.1.3 Alnylam RNAi Therapy Introduction
11.1.4 Alnylam Revenue in RNAi Therapy Business (2018-2023)
11.1.5 Alnylam Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics RNAi Therapy Introduction
11.2.4 Sarepta Therapeutics Revenue in RNAi Therapy Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Alnylam Pharmaceuticals
11.3.1 Alnylam Pharmaceuticals Company Detail
11.3.2 Alnylam Pharmaceuticals Business Overview
11.3.3 Alnylam Pharmaceuticals RNAi Therapy Introduction
11.3.4 Alnylam Pharmaceuticals Revenue in RNAi Therapy Business (2018-2023)
11.3.5 Alnylam Pharmaceuticals Recent Development
11.4 Moderna
11.4.1 Moderna Company Detail
11.4.2 Moderna Business Overview
11.4.3 Moderna RNAi Therapy Introduction
11.4.4 Moderna Revenue in RNAi Therapy Business (2018-2023)
11.4.5 Moderna Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi RNAi Therapy Introduction
11.5.4 Sanofi Revenue in RNAi Therapy Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 Arcturus Therapeutics
11.6.1 Arcturus Therapeutics Company Detail
11.6.2 Arcturus Therapeutics Business Overview
11.6.3 Arcturus Therapeutics RNAi Therapy Introduction
11.6.4 Arcturus Therapeutics Revenue in RNAi Therapy Business (2018-2023)
11.6.5 Arcturus Therapeutics Recent Development
11.7 Silence
11.7.1 Silence Company Detail
11.7.2 Silence Business Overview
11.7.3 Silence RNAi Therapy Introduction
11.7.4 Silence Revenue in RNAi Therapy Business (2018-2023)
11.7.5 Silence Recent Development
11.8 Sirnaomics
11.8.1 Sirnaomics Company Detail
11.8.2 Sirnaomics Business Overview
11.8.3 Sirnaomics RNAi Therapy Introduction
11.8.4 Sirnaomics Revenue in RNAi Therapy Business (2018-2023)
11.8.5 Sirnaomics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details